Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies)New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the hear ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies)New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the hear ...

Potential Benefits of GLP-1s in Children - GLP-1s may offer cardiovascular benefits to children at high risk, similar to those observed in adults [2] - GLP-1s may reduce the risk of serious conditions like dementia, Alzheimer's, heart disease, and cancers in children, mirroring adult outcomes [1] Risks and Considerations - There is limited scientific data on the long-term effects of GLP-1s in children [1] Disease Progression in Children - Co-morbidities like pre-diabetes and cardiovascular disease risk can be more aggressive in children [2]

Cardiovascular Disease & Scar Tissue - Cardiovascular disease leads to one death every 33 seconds in the US, with scar tissue from heart attacks being a major cause [3][4] - Scar tissue, while preventing holes in the heart, impairs heart function, leading to heart failure as the heart muscle compensates for the non-functional scar tissue [6][7][8] - Unlike mammals, zebrafish can degrade scar tissue and regenerate heart tissue, despite the scar tissue being primarily composed of collagen [9][10] Collagen Cross-linking & TMRO Probe - The research indicates that the *type* of collagen cross-linking, rather than the *extent*, determines scar tissue degradability [32] - Mammalian scar tissue has "locked" collagen cross-links (specifically pyodenoline or PYD), making it difficult to degrade, while zebrafish have "open" cross-links [33][34][36][37] - The company developed a molecular imaging probe, TMRO, to detect collagen cross-linking, enabling reduced animal usage in research by visualizing the process [19][20][18] Fibrotic Diseases & Future Implications - This research has implications for fibrotic diseases, which account for 30-50% of deaths in the industrialized world, by potentially inhibiting the formation of "locked" collagen cross-links [37][38] - The company's mission is to inhibit the formation of these locks, allowing scar tissue to be degraded, restoring organ function, and preventing a large number of deaths [38]

Core Insights - Amgen Inc. is experiencing positive momentum in its business as the first half of 2025 approaches its conclusion [3] - The company reported a 9% increase in first-quarter revenues and a 24% rise in non-GAAP EPS year-over-year, driven by strong performance across its product portfolio [4] - Fourteen products within Amgen's portfolio achieved double-digit growth in the first quarter of 2025 [4] Financial Performance - First-quarter revenues reached a growth of 9% year-over-year [4] - Non-GAAP EPS increased by 24% compared to the previous year [4] - Repatha, a key product, generated $656 million in revenue for Q1 2025, marking a 27% increase [4] Market Context - Cardiovascular disease continues to be a leading cause of mortality globally, which supports the ongoing demand for Amgen's products [5]